Curar-el-brazo-con-la-magia-de-la-biotecnologia-11-1200x850.jpg

Biotechnology to treat fractures - Scientific research IDCBIS.

Biotechnology may seem like magic 🧙‍♂️

Our researchers at the IDCBIS Tissue Engineering Unit know this, and have decided to use this power to improve the health of the community 😁.

For this reason we are developing 3D Quyne, an alternative for patients who suffer fractures, using polylactic acid, a material that is being investigated for the first time in Colombia for its ability to allow the passage of nutrients, help bone regeneration and prevent the muscle from invading the area in recovery.

The #Biotecnología y la #Investigacioncientifica are today a hope for the development of personalized medicine in our country. Patients who in the future would see a more effective recovery would be the testimonies that would accompany the development of this research 👏🏼.

Curar el brazo con la magia de la biotecnología-01

Curar el brazo con la magia de la biotecnología-02

Curar el brazo con la magia de la biotecnología-03

Curar el brazo con la magia de la biotecnología-04

Curar el brazo con la magia de la biotecnología-05

Curar el brazo con la magia de la biotecnología-06

Curar el brazo con la magia de la biotecnología-07

Curar el brazo con la magia de la biotecnología-08

Curar el brazo con la magia de la biotecnología-09

Curar el brazo con la magia de la biotecnología-10

The dangerous Clonazepam challenge in social networks.

From the Pharmaceutical Biotechnology Unit we inform you of the consequences of inappropriate use of clonazepam. We believe that a good way to prevent is to inform ourselves 😁.

👉 Clonazepam is a medicine used to treat mental and nervous system disorders such as anxiety, panic disorder and seizure disorder. It is also used to relieve symptoms of certain movement disorders. It is a type of medicine called a benzodiazepine, which helps relax muscles and reduce anxiety.

As we told you, there are great risks to your health if you do not consume it properly. Even an excess in consumption can have very negative consequences 🙁

According to our @minsalud, the clonazepam is a medicine of special control "because it produces effects of psychic or physical dependence in the human being; or it can have some degree of danger in its use". You can consult it in its web page.

Dangerous Clonazepam Challenge

#farmaceuticaclinica #quimicafarmaceutica #divulgacioncientifica

Get to know all our outreach content on Instagram @IDCBIS

The District Tissue Bank of the District Institute of Science, Biotechnology and Innovation in Health (IDCBIS) has established itself as a reference bank in Latin America, training health professionals from different countries of the continent, this time the turn was for Chile.

August 26, 2022. The tissue bank of Iquique, Chile, is developing a project that arises from the need of skin allografts for the management of burn patients. In Chile, on average there is only one skin donor in the country per year, therefore, the availability of cadaveric donor skin for transplantation is almost null. This opened the need for the use of living donor skin from body contouring surgeries.

In order to improve, grow and have the standards that a tissue bank requires, doctors Aldo Cañete, children's surgeon and director of the Regional Skin and Tissue Bank; Luana Mandriaza, coordinator of the Regional Bank; Jennifer Gómez, nurse in charge of organ and tissue procurement; María José Pulgar, nurse coordinator of the skin program and Dr. Marcelo Fonseca, plastic surgeon, arrived in Bogotá on August. Marcelo Fonseca, plastic surgeon, arrived in Bogota on August 22 and during their visit they have been trained in the processes of rescue, processing and quality management of lamellar tissue, skin, amniotic membrane and acellular dermis at the IDCBIS District Tissue Bank.

During their visit, the professionals of the Tissue Bank of Iquique attended the Burn Unit of the Simon Bolivar Hospital, as a referral in the integral treatment of the burned patient.

The District Tissue Bank of the District Institute of Science, Biotechnology and Innovation in Health (IDCBIS) is the only multipurpose public bank in the country and the first in Latin America with development and standardization in acellular dermis to favor the regeneration of definitive skin in burn patients. The Bank has INVIMA certification in good practices for ocular, musculoskeletal and skin tissue, in addition to being pioneers in Colombia in the amniotic membrane donation program, tissue that is used for the treatment of burn patients and for ophthalmology and maxillofacial surgery specialties.

"This knowledge that IDCBIS has given us will help our patients in Chile, since we are the only ones who process skin and we will be able to perfect our processes to improve the quality of life of many people," said Dr. Marcelo Fonseca, plastic surgeon.

This referral visit was possible thanks to the willingness of the Bank's staff headed by the director of IDCBIS, Dr. Bernardo Camacho, who has been leading international cooperation agreements that allow the consolidation of a scientific and medical community in the country and the region around research and altruism of citizenship.

The District Tissue Bank IDCBIS will donate the skin to attend burn patients in the Mantanzas region of Cuba.

August 19, 2022. On August 5, in the province of Matanzas, Cuba, a fire broke out in an industrial zone due to a lightning strike in an oil storage facility, which caused the conflagration, leaving more than 60 people injured with burns.

The District Tissue Bank IDCBIS, an entity linked to the District Health Secretariat, as humanitarian aid has donated 3 thousand cm2 of skin to the Cuban Government to help in the recovery of the wounded from the massive fire that occurred in this country.

The donation was made thanks to the efforts of the Colombian Ministry of Health in alliance with the Cuban Vice-Ministry of Health, the Cuban Ambassador to Colombia and the District Institute of Science, Biotechnology and Innovation in Health (IDCBIS) linked to the District Health Secretariat of Bogota.

The Director of IDCBIS, Bernardo Camacho, stated that "in addition to expressing the generosity and international solidarity of this donation with the tragedy, it is the recognition of the high quality and trust in the IDCBIS District Tissue Bank to distribute to burn patients who need this tissue for their recovery. These tissues were rescued from Colombian donors, complying with all safety and quality standards for the care of patients who require it."

The IDCBIS currently has the only multipurpose Tissue Bank in the country, which favors access to the most vulnerable population with transplant requirements and has the selection of donors, rescue, processing, preservation, storage and distribution of human tissues with high quality standards. It is the only multipurpose bank in the country and the first in Latin America with development and standardization in acellular dermis to improve the regeneration of definitive skin in burn patients.

The Bank processes cornea and sclera, skin, musculoskeletal tissue and amniotic membrane for use in ophthalmology, plastic surgery and maxillofacial surgery.

Media coverage

Telesur: Colombia donates skin for burned patients of the fire in Cuba

Infobae: Colombia to donate 3,000 centimeters of skin to Cuba as part of humanitarian aid for the emergency in Matanzas

El Colombiano: Colombia joins humanitarian aid to Cuba: will donate skin for the injured in Matanzas

galardonado con la ORDEN CIVIL AL MÉRITO Dona Bogotá 2017-2018-2019 About the District Tissue Bank

The institute has been recognized for meeting very strict criteria, as well as for its advances in research.

Note originally published in: ediciónmedica.com

The District Institute of Science, Biotechnology and Innovation in Health (IDCBIS), has informed the entire community, both scientific and academic, that the Transfusion, Tissue and Cellular Medicine Research Group (GIMTTYC) has obtained the classification of "Transfusion, Tissue and Cellular Medicine" group. A1 research by the Ministry of Science, Technology and Innovation.

It should be noted that the group GIMTTYC is an interdisciplinary group with actions aimed at the development of three main areas in health: transfusion medicine, tissue and cellular therapy.

Its objective has been to identify health problems in the areas of transfusion medicine, tissue and cellular therapy in order to contribute in the solution through the development of research projects based on ethical criteria, that generate new knowledge, strengthen the training of researchers and consolidate research networks.

In interview with MEDICAL EDITION, Bernardo Camacho, director of the IDCBIS, said that "in the last call for applications more than 7,000 research groupsThe application is very rigorous, but in the end, a small group obtained the recognition, 849 groups remained".

Camacho explained that, "in group A there are 1,174, in group B there are 1,830 and in group C there are 2,376 groups. The A group has the least number of groups, but there are still 531 recognized groups."He added that "the A1 group is for research, which is like the top, in the sense that it is required to rigorously comply with the criteria to be in this group".

"In our case for the last four years we were in group C, but now we go up to A1 this is due to several factors, firstly having a senior researcher, international, scientific publications in high impact indexed journals," Camacho pointed out.

"For us that was very important because we were recognized in the field of health sciences, but we specifically have a research focus in the area of advanced cell therapies, among others. So we were recognized because we have carried out a great deal of scientific research and even original research in the focus that we have," said Camacho.

The director also explained that they train master's and doctoral students, and also have associate and senior researchers. "We are implementing the inclusion of more senior researchers."

"That designation is earned by all the achievements that the research group has made, but in October of the previous year we were recognized as a research center for the next five years, this due to the strength in information and scientific production, which performs the team of scientists who are working with us," Camacho has pointed out.

Researchers at the Advanced Therapies Unit of the IDCBIS (District Institute of Science, Biotechnology and Innovation in Health) are making progress in the research on the biology of the mesenchymal cells and its possible applications in medicine that allow to improve the quality of life of patients with different conditions, since it has been observed that they modulate adverse reactions in different diseases, especially in degenerative and autoimmune diseases.

Mesenchymal cells regenerate and repair damaged tissues and replace cells that routinely die, they are characterized by a great capacity for expansion and differentiation, which allows them to renew themselves easily and give rise to various cell types, such as bone, adipose and cartilage cells; they also have the capacity for tissue regeneration, aiding healing, preventing cell death and facilitating the formation of new blood vessels.

The IDCBIS laboratories are researching and evaluating the potential of mesenchymal stem cells, which are extracted from umbilical cords donated by Colombian mothers, to reduce inflammation and regulate the activity of immune system cells in multiple diseases.

In addition, tissue engineering research is focused on the generation of structures that support mesenchymal stem cells for the regeneration/repair of skin (burns and ulcers), bone (fractures and bone loss) and cartilage (osteoarthritis).

At the same time, simulation models are being developed using mesenchymal cells to recreate metabolic diseases of genetic origin and thus evaluate the efficacy of the drugs used in these pathologies.

Currently the only approved treatment in the world is the transplantation of blood-forming cells present in the bone marrow or in peripheral blood taken from a donor or from the patient himself. Other treatments involving the use of stem cells, as in the research carried out at IDCBIS, are in the experimental phase.

This research project, among others currently being developed at IDCBIS, is being carried out under the leadership of the Institute's Director, Dr. Bernardo Camacho, who was recently re-elected as the Institute's leader by unanimous vote of the Board of Directors, composed of the Pontificia Universidad Javeriana, the Universidad Nacional, the Universidad de Los Andes, the Instituto Nacional de Cancerología and the Alcaldía Mayor de Bogotá - Secretaría Distrital de Salud together with the integrated health services sub-networks: Centro Oriente, Sur Occidente and Norte.

Blog